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Abstract
Background: Scarce data are available on Plasmodium falciparum anti-malarial drug resistance in Pakistan. The aim
of this study was, therefore, to determine the prevalence of P. falciparum resistance associated polymorphisms in
field isolates from southern Pakistan.
Methods: Blood samples from 244 patients with blood-slide confirmed P. falciparum mono-infections were
collected between 2005-2007. Single nucleotide polymorphisms in the P. falciparum chloroquine resistance
transporter (pfcrt K76T), multi drug resistance (pfmdr1 N86Y), dihydrofolate reductase (pfdhfr A16V, N51I, C59R,
S108N, I164L) and dihydropteroate synthetase (pfdhps A436S, G437A and E540K) genes and pfmdr1 gene copy
numbers were determined using PCR based methods.
Results: The prevalence of pfcrt 76T and pfmdr1 86Y was 93% and 57%, respectively. The prevalence of pfdhfr
double mutations 59R + 108N/51R + 108N was 92%. The pfdhfr triple mutation (51I, 59R, 108N) occurred in 3% of
samples. The pfdhfr (51I, 59R, 108N) and pfdhps (437G, 540E) quintuple mutation was found in one isolate. Pfdhps
437G was observed in 51% and 540E in 1% of the isolates. One isolate had two pfmdr1 copies and carried the
pfmdr1 86Y and pfcrt 76T alleles.
Conclusions: The results indicate high prevalence of in vivo resistance to chloroquine, whereas high grade
resistance to sulphadoxine-pyrimethamine does not appear to be widespread among P. falciparum in southern
Pakistan.
Background
Development and spread of Plasmodium falciparum
resistance to anti-malarial drugs represents a major
threat to global malaria control. In Pakistan, an esti-
mated 500,000 episodes of malaria infection occur
annually [1]. The incidence of malaria has markedly
increased during the last decade and the relative fre-
quency of P. falciparum amongst blood-slide positive
malaria infections has increased from 45% in 1995 to
68% in 2006 [2-4], probably due to increasing resistance
to commonly used monotherapies.
Chloroquine resistance was first reported from
Pakistan in 1984 and was followed by several reports
confirming it in Punjab, Afghan refugee camps and
areas bordering Afghanistan [5-8]. In agreement with
recommendations by the World Health Organization,
Pakistan has adopted artemisinin-based combination
therapy (ACT) as treatment of choice for uncomplicated
P. falciparum malaria with artesunate plus sulphadox-
ine-pyrimethamine as first-line treatment [9]. However,
the use of this combination is of some concern as resis-
tance to sulphadoxine-pyrimethamine monotherapy has
been reported from western Pakistan [10].
Analyses of molecular markers associated with P.
falciparum anti-malarial drug resistance can provide
important information about levels of sulphadoxine-
pyrimethamine resistance. Single nucleotide polymorph-
isms (SNPs) at codons 51, 59, 108 and 164 in the P.
falciparum dihydrofolate reductase gene (pfdhfr) are
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well established determinants of pyrimethamine resis-
tance [11]. An initial mutation at codon 108 causes 7-50
fold increase in the in vitro inhibitory concentration
(IC50). The presence of additional mutations further
increase IC50 and the triple mutant (N51I/C59R/
S108N) is associated with clinical treatment failure
[12,13]. Similarly, mutations at codons 436, 437, 540,
581 and 613 in the P. falciparum dihydroptereoate
synthase gene (pfdhps) are associated with sulphadoxine
resistance [14,15].
Other genetic polymorphisms have also been asso-
ciated with P. falciparum drug tolerance/resistance. The
K76T amino acid substitution in the chloroquine resis-
tance transporter gene (pfcrt) has been shown to be
essential for chloroquine resistance, associated with amo-
diaquine resistance and predictive of treatment failure for
both drugs [16,17]. Pfcrt 76K has been associated with
lumefantrine tolerance/resistance and higher IC50 values
[18-20]. The P. falciparum multidrug resistance gene 1
(pfmdr1) allele 86Y has been associated with chloroquine
and amodiaquine resistance and increased chloroquine
IC50 values in P. falciparum with pfcrt 76T [21,22]. In a
meta analysis pfmdr1 86Y was significantly linked to
chloroquine and amodiaquine resistance [23]. Conver-
sely, pfmdr1 86N has been associated with lumefantrine
tolerance/resistance and higher lumefantrine IC50
[20,24,25]. Pfmdr1 amplifications are associated with
mefloquine resistance in vivo and in vitro, doubled lume-
fantrine IC50 and reduced sensitivity to artesunate [26].
Scarce data are available on anti-malarial drug resis-
tance among the P. falciparum population in Pakistan.
The aim of this study was, therefore, to assess the preva-
lence of P. falciparum resistance associated polymorph-
isms in field isolates from southern Pakistan.
Methods
Study setting, participants and ethics
The study was conducted between October 2005 and
October 2007 at the Aga Khan University Hospital, a
tertiary hospital located in central Karachi, and its estab-
lished chain of primary health care and diagnostic ser-
vice centres located in Sindh and Baluchistan provinces,
Pakistan. In the study area, malaria transmission peaks
during and after the monsoon season that lasts from
June to October. Patients with microscopy confirmed P.
falciparum mono-infection were eligible for enrolment
irrespective of age, sex and disease severity.
The study was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice
[27]. Informed consent was obtained from all partici-
pants or in case of children from their parents/legal
guardians. The study was approved by the ethical
review committee of Aga Khan University Hospital,
Karachi, Pakistan.
Blood collection and microscopy
Two ml of intravenous blood were collected in an
EDTA tube from all patients referred to the laboratory
for investigation of malaria infection. For screening pur-
poses a thick blood film was prepared and analysed
using Leishman stain according to routine practice. In
case of a positive screening result, a thick and thin
Giemsa-stained blood film was prepared for confirma-
tion of the presence of malaria parasites and species
identification. For all patients with confirmed P. falci-
parum mono-infection the parasite density was assessed
by counting asexual parasites against 200 white blood
cells (WBC) on the thick film and quantified (parasites/
μl) by assuming an average of 8000 WBC per μl blood
[28]. All blood slides were examined by experienced
microscopists at the clinical laboratory of Aga Khan
University Hospital. For quality control, 10% of the
blood slides were re-examined by an independent
microscopist unaware of the initial result.
From each sample 100 μl of blood was spotted on an
FTA® filter paper (Whatman), dried, then put in a sepa-
rate plastic bag and stored at -80°C. The remaining
blood was transferred to cryo-vials and kept frozen at
-80ºC until used for DNA extraction. A brief epidemio-
logical and demographic history was also collected from
each participant using a structured questionnaire.
DNA extraction
DNA was extracted using Qiamp DNA mini Kits (Qia-
gen, USA) from 200 μl of whole blood at Aga Khan
University Hospital. The FTA® filter papers were trans-
ported to Karolinska Institutet, where DNA was
extracted from approximately half of each blood sample
(50 μl) using an ABI Prism® 6100 Nucleic Acid Prep
Station (Applied Biosystems, Fresno, CA). In both cases
DNA extraction was according to the manufacturer’s
instructions. Extracted DNA was stored at -20°C until
amplified by PCR.
Genotyping
Pfcrt K76T and pfmdr1 N86Y alleles were analysed for
all samples at Aga Khan University Hospital. Quality
control was done at Karolinska Institutet by genotyping
a randomly selected subset of 25% of the samples. The
same multiplex PCR-RFLP protocol [29] was used at
both laboratories.
SNPs at pfdhfr codons 16, 51, 59, 108 and 164, and
pfdhps codons 436, 437 and 540 were identified by
sequencing according to a previously described method
[30]. The PCRs were performed at Karolinska Institutet.
The products were purified and sequenced commercially
(Macrogen Inc. Seoul, Korea). For quality control, the
genotype at codon 540 was determined from 25% of the
samples using a PCR-RFLP based method [29]. Codon
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540 was chosen because of its location towards the end
of the amplified segment, where sequencing is less
robust. PCR and restriction products were resolved on
2% agarose gels (Amresco, Solon, OH). All gels were
stained with ethidium bromide and visualized under UV
transillumination (GelDoc®, Biorad, Hercules, Ca, USA).
Pfmdr1 gene copy number variation polymorphism
was determined using real time PCR (ABI Prism® 7000
Sequence Detection System) as previously described
[26]. All samples were run in triplicate. The clones,
3D7, D10 and K1 were used as single copy calibrators
and FCB and Dd2 represented multiple copy controls.
Pfmdr1 copy numbers were calculated using a compara-
tive threshold method (ΔΔCt method) [26]. An amplifi-
cation of pfmdr1 was defined as copy number >1.6.
Assays were repeated if the following results were
obtained: copy number 1.3-1.6 or Ct value >35 or ΔΔCt
spread >1.5.
Power calculation and statistical analyses
This was a descriptive/exploratory study precluding a
power calculation of sample size. Data were entered,
validated and analysed using SPSS version 16.0. The
Sequencher ™ software version 4.6 (Gene Codes Cor-
poration, Ann Arbor, MI) was used to analyse the
sequences output using the 3D7 clone sequence
obtained from NCBI database (pfdhfr Accession #
JO4643 and pfdhps XM_001349382) as a reference.
Allele proportions were calculated as the number carry-
ing a certain allele divided by the number of samples
with positive PCR outcome. Mixed infections thus con-
tribute to the prevalence of both alleles.
Results
Patients
A total of 244 patients with microscopy confirmed P.
falciparum mono-infection were enrolled. Baseline
demographic data are presented in Table 1.
Pfcrt and pfmdr1 SNPs
Pfcrt K76T and pfmdr 1 N86Y were successfully ampli-
fied in 240/244 (98%) samples. Allele proportions are
presented in Table 2. Pfcrt 76T and pfmdr1 86Y occurred
together in 127/240 (53%) patients. Pfcrt 76T and pfmdr1
86N were observed in 96/240 (40%) of patients. Pfcrt 76K
and pfmdr1 86N were found together in 8/240 (3%). PCR
amplification failed repeatedly in 4/244 (2%) samples. For
that reason these samples were excluded from further
PCR analyses (pfmdr1 copy number, pfdhfr and pfdhps)
Pfmdr1 copy number
The real-time PCR was successful in 232/240 (97%)
samples. A single pfmdr1 gene was found in 231 sam-
ples. One sample had 2 copies of the pfmdr1 gene and
carried the pfmdr1 86Y and pfcrt 76T alleles.
Pfdhfr and pfdhps
PCR amplifications and sequencing of pfdhfr and pfdhps
were successful in 218/240 (91%) and 231/240 (96%)
samples, respectively. The prevalence of SNPs at codon
51, 59 and 108 of pfdhfr and codon 436, 437 and 540 of
pfdhps are presented in Table 3. The pfdhfr alleles
108T, 16V and 164L were not observed.
Table 1 Baseline characteristics of enrolled patients
All
(n = 244)
Karachi
(n = 182)
Sindh
(n = 52)
Baluchistan
(n = 10)
Age *
≤5 years 35 (0.14) 16 (0.09) 17 (0.33) 2 (0.20)
6-15 years 39 (0.16) 26 (0.14) 12 (0.23) 1 (0.10)
>15 years 170 (0.70) 140 (0.77) 23 (0.44) 7 (0.70)
Sex*
Male 173 (0.71) 137 (0.75) 31 (0.60) 5 (0.50)
Female 71 (0.29) 45 (0.25) 21 (0.40) 5 (0.50)
Parasite density§ (parasites/μl) 11100 (80-540000) 12720 (80-540000) 7480 (80-126000) 66160 (240-230220)
Gametocyte carriage 96 (0.45) 69 (0.43) 23 (0.48) 4 (0.45)
* Number of patients are presented with proportions in brackets.
§ Parasite densities were available form 216 patients. Median data are presented with range in brackets.
Table 2 Prevalence of pfcrt 76K, 76T, pfmdr1 86N and 86Y
alleles in southern Pakistan
Pfcrt Pfmdr 1
n 76K 76T 76T/K 86N 86Y 86Y/N
Karachi 178 16
(0.09)
161
(0.91)
1
(0.006)
73
(0.41)
84
(0.47)
21
(0.12)
Sindh 52 0 52 (1) 0 25
(0.48)
20
(0.39)
7
(0.14)
Baluchistan 10 1
(0.10)
9 (0.90) 0 6 (0.60) 4 (0.40) 0
Total 240 17
(0.07)
222
(0.93)
1
(0.004)
104
(0.43)
108
(0.45)
28
(0.12)
Allele proportions are shown in brackets.
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The pfdhfr double mutation 59R + 108N was found in
190/218 (87%) and 51I + 108N was found in 11/218
(5%) samples. The prevalence of pfdhfr double muta-
tions 51I + 108N/59R + 108 was 201/218 (92%). The
pfdhfr triple mutation (51I, 59R, 108N) occurred in 7/
218 (3%) samples. The above mentioned pfdhfr triple
mutation haplotype was found together with pfdhps
437G in one sample. The combined pfdhfr (51I, 59R,
108N) and pfdhps (437G, 540E) quintuple mutation was
found in one isolate from Karachi. The pfdhfr 51, 59,
108,164 and pfdhps 436, 437 and 540 haplotypes are
presented in Table 4. Thirteen different pfdhfr-pfdhps
haplotypes were identified.
Discussion
This is the most comprehensive report characterizing
resistance associated genetic polymorphisms in P. falci-
parum field samples collected in southern Pakistan. As
such, the results bridge an important knowledge gap of
the P. falciparum population in South Asia.
The 93% prevalence of pfcrt 76T, essential for chloro-
quine resistance, is in line with results from neighbouring
countries [16,31,32]. This data indicate high levels of
in vivo P. falciparum chloroquine resistance in southern
Pakistan. Moreover, the high pfcrt 76T and moderately
high (57%) pfmdr1 86Y prevalence also suggests high levels
of tolerance/resistance to amodiaquine in the study area.
The high prevalence of the pfdhfr 108N (99%) and 51I
+ 108N/59R + 108N (92%) in our study indicate that
decreased susceptibility to sulphadoxine-pyrimethamine
is widespread in Pakistan. However, only seven patients
had infections with the triple pfdhfr resistance associated
haplotype and only one patient was infected with P.
falciparum that had the quintuple pfdhfr + pfdhps hap-
lotype associated with high grade sulphadoxine-pyri-
methamine resistance. These results indicate that high
grade resistance to sulphadoxine-pyrimethamine is not
widespread and suggest that this drug is probably suita-
ble for use with artesunate in southern Pakistan,
as recommended by the National Malaria Control
Table 3 Prevalence of resistance associated single nucleotide polymorphisms in pfdhfr and pfdhps from southern
Pakistan
Pfdhfr Pfdhps
n 51I 59R 108N n 436A 437G 540E
Karachi 161 16 (0.1) 144 (0.89) 159 (0.99) 170 1 (0.006) 99 (0.58) 3 (0.02)
Sindh 48 2 (0.04) 44 (0.92) 47 (0.98) 51 0 13 (0.26) 0
Baluchistan 9 0 9 (1) 9 (1) 10 0 6 (0.60) 0
Total 218 18 (0.08)* 197 (0.90)§ 215 (0.99) 231 1 (0.004) 118 (0.51) 3 (0.01)†
Allele proportions are shown in brackets. Pfdhfr alleles 108T, 16V and 164L were not observed.
* 3/218 had mix infection with pfdhfr 51I and 51N alleles, § 5/218 had mix infection with pfdhfr 59C and 59R alleles.
† 2/231 had mix infection with pfdhps 540E and 540K allele.
Table 4 Prevalence of pfdhfr- pfdhps haplotypes in P. falciparum isolates from southern Pakistan
Pfdhfr N51I, C59R, S108N, I164L
Pfdhps S436A, A437G, K540E*
No. of isolates
No. of
mutations
Karachi
(n = 158)
Sindh
(n = 47)
Baluchistan
(n = 9)
Total
(n = 214)
NCSI-SAK 0 - 1 (0.02) - 1 (0.005)
NRNI-SGK 3 80 (0.51) 9 (0.19) 5 (0.55) 94 (0.44)
NRNI-SAK 2 55 (0.35) 33 (0.70) 4 (0.45) 92 (0.43)
IRNI-SGK 4 1 (0.006) - - 1 (0.005)
IRNI-SGE 5 1 (0.006) - - 1 (0.005)
IRNI-SAK 3 4 (0.03) 1 (0.02) - 5 (0.02)
ICNI-SAK 2 5 (0.03) - - 5 (0.02)
ICNI-SGK 3 3 (0.02) 1 (0.02) - 4 (0.02)
ICNI-SGE 4 2 (0.01) - - 2 (0.01)
NCNI-SAK 1 3 (0.02) - - 3 (0.01)
NCNI-SGK 2 2 (0.01) 2 (0.04) - 4 (0.02)
NCSI-AAK 1 1 (0.006) - - 1(0.005)
NCSI-SGK 1 1 (0.006) - - 1(0.005)
pfdhfr-pfdhps haplotypes proportions are shown in brackets.
* Resistance associated alleles are indicated in bold.
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Programme. However, the occurrence of triple and
quintuple mutant P. falciparum is of concern as wide-
spread use of sulphadoxine-pyrimethamine as a partner
to artesunate may rapidly select these haplotypes. Moni-
toring of pfdhfr and pfdhps resistance associated haplo-
types is consequently of importance. Furthermore,
artesunate + sulphadoxine-pyrimethamine in vivo effi-
cacy urgently needs to be assessed. This is critical as
efficacy studies conducted in Baluchistan (2001-2005)
reported 56% treatment failure with sulphadoxine-pyri-
methamine monotherapy [33]
Only one patient had a P. falciparum infection with
two copies of pfmdr1, a finding that should be inter-
preted with caution. Increased pfmdr1 copy number has
been associated with an increased risk for treatment fail-
ure after mefloquine monotherapy and artesunate-
mefloquine therapy [26]. The low prevalence of pfmdr1
amplifications observed in this study suggests that both
artesunate-mefloquine and artemether-lumefantrine
would be efficacious in southern Pakistan. They may
therefore represent potential future treatment alterna-
tives to artesunate + sulphadoxine-pyrimethamine.
Furthermore, the observed low prevalence of pfcrt 76K
and pfmdr1 86N provides supporting evidence of a
probable high artemether-lumefantrine efficacy [20,24]
This data concur with recent results from a small
study (n = 28) conducted in Khyber Pkhtunkhwan Pro-
vince, Pakistan and previous data from India and Iran
[34]. Furthermore, just as in northern India and Iran the
pfdhfr A16N51R59N108I164 and A16I51R59N108I164 were
the most common double and triple mutants found
[35,36]. These results thus support a selective sweep of
chloroquine and sulphadoxine-pyrimethamine resistant
P. falciparum from southeast Asia via India to Pakistan
and then on to Iran [37-40]
It should be underlined that a majority of patients
(74%) presented with symptomatic malaria infection at
the Aga Khan University Hospital that represents tertiary
level of care. Some of these patients may have received
anti-malarial treatment prior to enrolment in this study
and the P. falciparum SNP proportions reported may,
therefore, not be representative for the parasite popula-
tion in southern Pakistan. However, the similarity of our
results with those reported from neighbouring countries
suggests that the results may be generalized.
Conclusion
The results indicate high prevalence of in vivo resistance
to chloroquine among P. falciparum in southern
Pakistan, but high grade resistance to sulfadoxine-pyri-
methamine does not appear to be widespread in the
parasite population. This data thus support the recent
change of first line therapy for uncomplicated P. falci-
parum malaria from chloroquine to artesunate +
sulphadoxine-pyrimethamine. Continued anti-malarial
drug resistance surveillance in Pakistan is essential.
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